Ranibizumab for Neovascularization in Sickle Cell Retinopathy

NCT00618644 · clinicaltrials.gov ↗

NA

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Withdrawn due to lack of eligible participants

Conditions

Sickle Cell Anemia
Retinopathy

Interventions

DRUG: Ranibizumab

Sponsor

Kresge Eye Institute

Collaborators

[object Object]
[object Object]